Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin for Religious Leaders
NCT02421263Phase 1Completed
- Sponsor
- NYU Langone Health
- Start
- Apr 2015
- Primary completion
- Jun 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of psilocybin (2 arms), sponsored by NYU Langone Health. Primary endpoint: Interim Questionnaire at 6 months. Started Apr 2015; status: completed.
02
Drugs
psilocybin
Beyond the preview
Go deeper on NCT02421263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02421263.